22:00 , Jun 18, 2018 |  BC Extra  |  Company News

Management tracks: Ionis, Albireo

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) hired Damien McDevitt as CBO. He was SVP of corporate development at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). Hepatic disease company Albireo Pharma Inc. (NASDAQ:ALBO) hired Jason Duncan as general counsel. He was general...
23:54 , Aug 7, 2017 |  BC Extra  |  Company News

Management tracks: Pfenex, Alvotech, uniQure

Biosimilars company Pfenex Inc. (NYSE-M:PFNX) named Evert Schimmelpennink CEO, president and secretary. He succeeds interim CEO Patrick Lucy, who will continue as CBO. Rasmus Rojkjaer was named CEO at biosimilar company Alvotech ehf (Reykjavik, Iceland),...
22:43 , Jun 8, 2017 |  BC Innovations  |  Translation in Brief

TGFβ on the brain

Against a checkered past of TGFβ signaling in preclinical models of Parkinson’s disease, a Stanford University team has provided new evidence that stimulating the pathway holds promise in the indication. Stanford and SRI International have...
20:10 , May 25, 2017 |  BC Innovations  |  Translation in Brief

Youthful memories

Alkahest Inc. co-founder and Stanford University researcher Tony Wyss-Coray has followed up his earlier discovery of blood factors in the elderly that contribute to cognitive decline by finding an umbilical cord blood factor that may...
21:10 , Mar 17, 2017 |  BioCentury  |  Finance

Practice makes Pivotal

Newly launched Pivotal bioVenture Partners plans to join syndicates funding early stage companies until it finishes building out its team and can begin to lead investments and play a larger role in the company-building process....
13:10 , Mar 16, 2017 |  BC Extra  |  Financial News

Pivotal debuts with $301M life sciences fund

Pivotal bioVenture Partners launched with a $301 million fund to invest in early stage therapeutics companies. Managing partners Tracy Saxton and Vincent Cheung co-founded the firm. Saxton previously held investment roles at Roche Venture Fund...
07:00 , Sep 12, 2016 |  BioCentury  |  Emerging Company Profile

Age factors

Alkahest Inc. is identifying factors in human plasma that could serve as therapeutics or novel targets used to treat age-related conditions, including Alzheimer's disease. The newco's work stems from the lab of co-founder Tony...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

J&J other, pharmaceuticals news

Johnson & Johnson launched the fourth incubator in its JLABS network, located in South San Francisco, and named the first 10 companies in residence. J&J said the incubator can accommodate up to 50 startups. Eight...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Alkahest, Grifols deal

The companies partnered to develop plasma-based therapies to treat cognitive decline in aging and CNS disorders. Grifols will acquire a 45% stake in Alkahest for $37.5 million in cash and will receive worldwide commercialization rights...
01:52 , Mar 5, 2015 |  BC Extra  |  Company News

Grifols partners with Alkahest, takes equity stake

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) and Alkahest Inc. will collaborate to develop plasma-based therapies to treat cognitive decline in aging and CNS disorders. Grifols will acquire a 45% stake in Alkahest for $37.5 million in cash,...